
ABIO
Healthcare · Biotechnology · $34.8M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 1, 2024 | After the close | — | -0.18 | — |
| Apr 25, 2024 | After the close | — | -0.14 | — |
| Feb 1, 2024 | After the close | — | -0.08 | — |
| Oct 18, 2023 | After the close | — | -0.10 | — |
| Jul 21, 2023 | After the close | — | -0.10 | — |
| Apr 24, 2023 | After the close | — | -0.09 | — |
| Feb 24, 2023 | After the close | — | -0.08 | — |
| Oct 28, 2022 | After the close | — | -0.16 | — |
| Aug 2, 2022 | After the close | — | -0.22 | — |
| May 2, 2022 | After the close | — | -0.55 | — |
| Mar 14, 2022 | After the close | -2.24 | -0.55 | +75.4% |
| Nov 2, 2021 | Time not confirmed | -2.30 | -0.33 | +85.7% |
| Aug 4, 2021 | Time not confirmed | -2.37 | -0.34 | +85.7% |
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode…
| Time not confirmed |
| -1.87 |
| -0.33 |
| +82.4% |
| Mar 18, 2021 | After the close | -2.44 | -0.55 | +77.5% |
| Nov 2, 2020 | Before the open | -2.51 | -0.33 | +86.9% |
| Aug 5, 2020 | After the close | -2.58 | -0.73 | +71.7% |
| May 6, 2020 | After the close | -2.04 | -0.83 | +59.3% |
| Feb 18, 2020 | After the close | -0.99 | -0.77 | +22.2% |
| Nov 6, 2019 | After the close | -1.30 | -0.76 | +41.5% |
| Aug 1, 2019 | After the close | -1.86 | -1.14 | +38.7% |
| May 8, 2019 | After the close | -1.98 | -1.86 | +6.1% |
| Feb 27, 2019 | After the close | -2.52 | -1.80 | +28.6% |
| Nov 14, 2018 | After the close | -3.42 | -1.98 | +42.1% |
| Aug 9, 2018 | After the close | -3.96 | -2.70 | +31.8% |
| May 8, 2018 | After the close | -3.60 | -3.60 | 0.0% |
| Mar 22, 2018 | After the close | -9.36 | -6.12 | +34.6% |